- Home
- IDR vs IMAB Comparison
IDR vs IMAB Comparison
Compare IDR & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- IMAB
- Stock Information
- Founded
- IDR 1996
- IMAB 2014
- Country
- IDR United States
- IMAB United States
- Employees
- IDR N/A
- IMAB N/A
- Industry
- IDR Precious Metals
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- IMAB Health Care
- Exchange
- IDR Nasdaq
- IMAB Nasdaq
- Market Cap
- IDR 378.0M
- IMAB 384.6M
- IPO Year
- IDR N/A
- IMAB 2020
- Fundamental
- Price
- IDR $27.79
- IMAB $4.38
- Analyst Decision
- IDR Strong Buy
- IMAB Strong Buy
- Analyst Count
- IDR 1
- IMAB 4
- Target Price
- IDR $17.50
- IMAB $6.75
- AVG Volume (30 Days)
- IDR 539.9K
- IMAB 2.1M
- Earning Date
- IDR 11-03-2025
- IMAB 11-02-2025
- Dividend Yield
- IDR N/A
- IMAB N/A
- EPS Growth
- IDR 57.55
- IMAB N/A
- EPS
- IDR 0.64
- IMAB N/A
- Revenue
- IDR $30,496,328.00
- IMAB N/A
- Revenue This Year
- IDR $21.91
- IMAB N/A
- Revenue Next Year
- IDR $5.47
- IMAB N/A
- P/E Ratio
- IDR $43.50
- IMAB N/A
- Revenue Growth
- IDR 59.64
- IMAB N/A
- 52 Week Low
- IDR $9.67
- IMAB $0.60
- 52 Week High
- IDR $29.69
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- IDR 64.61
- IMAB 54.65
- Support Level
- IDR $26.50
- IMAB $4.17
- Resistance Level
- IDR $29.69
- IMAB $4.69
- Average True Range (ATR)
- IDR 1.93
- IMAB 0.53
- MACD
- IDR -0.04
- IMAB -0.12
- Stochastic Oscillator
- IDR 74.25
- IMAB 25.44
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).